Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

4529004';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.nexavar.com/">www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors.  ONX 0801, a targeted alpha-folate inhibitor, is currently in Phase 1 testing. For more information about Onyx, v
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Cleveleys (UK) (PRWEB) March 05, 2015 ... implantable polymer have received the CE mark (European) approval. ... the European Free Trade Association (EFTA) and the European ... mark has now been granted to implants supplied by ... disc spinal conditions. , Osimplant's Cervical Expandable Bladed ...
(Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
(Date:3/4/2015)... PRC Clinical, a full-service, Contract ... Area, will exhibit and present at the Outsourcing ... March 25th and 26th in Tel Aviv, Israel. ... life science companies seeking to conduct U.S. Food and ... all phases of human trials, from Phase I studies ...
(Date:3/4/2015)... Jose, California (PRWEB) March 04, 2015 ... Reaction (PCR) represents one of the fastest growing technologies ... cell biologists in subcellular visualization is driving growth in ... need for deeper understanding of gene expressions will continue ... market. Expanding applications in fields ranging from pharma, biotech, ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... Listing and Attract Additional Investors ... as Company Enters Next Growth Phase, SAN DIEGO, May 8 ... (ICG),technology, today announced the reverse split of 1 for 7 shares ... Company,s,Annual Shareholders Meeting earlier today., The record date for the ...
... Calif., May 8 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... for 2008., For the first quarter ended March 31, ... per share, compared with a net loss of $15.3,million, or ... increase in,net loss was primarily due to $4.0 million in ...
... BEDFORD, Mass., May 8 Hologic, Inc. (Nasdaq:,HOLX) today ... at the Bank of America Healthcare Conference being held ... in Las Vegas, NV., Interested parties are invited ... presentation on Wednesday, May 14, 2008, at 1:20 p.m.,Eastern ...
Cached Biology Technology:CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 2CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 3Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 2Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 3Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 4Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 5Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 6
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Society applauds the Government of Argentina for creating two ... with majestic shorelines and abundant wildlife. The new ... Marine Parkwere recently established by the National Congress in ... other marine and coastal species., "We commend the Government ...
... This press release is available in German . ... of human infants was investigated using the prominent ,Stanford Marshmallow Experiment,: ... could either eat it now or wait and receive a second ... delay of several minutes. Interestingly, children that were able to wait ...
... study published online today in Nature Communications , researchers ... Sciences, BGI-Shenzhen, and University of Arizona have completed the genome ... provides new insights for researchers to understand the function and ... Oryza is an idea model system for studying plant ...
Cached Biology News:2 new marine protected areas created on Argentina's southern coasts 22 new marine protected areas created on Argentina's southern coasts 3Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
... is a dramatic breakthrough in accurate, small-volume bulk ... resolution, the micro 1 has unique advantages not ... micro 1 never needs re-calibration as do other ... on an LCD Display , Graphical Row Selection ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
... High performance agitation and temperature control for ... four wells independently and is suitable for ... L working volume. Its temperature ranges from ... Each well is equipped with an individual ...
Biology Products: